CNSide Diagnostics, a leader in precision diagnostics for central nervous system (CNS) cancers, is proud to announce the addition of Tramel Pennie to its growing team as Senior Laboratory Technician.

Tramel brings valuable experience in clinical laboratory operations and a passion for supporting innovative diagnostic solutions that improve patient care in neuro-oncology. In this role, Tramel will help advance the company’s proprietary CNSide® Cerebrospinal Fluid (CSF) Assay Platform, which enables earlier detection, monitoring, and treatment guidance for patients with leptomeningeal metastases (LM) and other CNS cancers.

“We’re excited to welcome Tramel to the CNSide team,” said Russell Bradley, President and General Manager. “His expertise and commitment to quality testing will further strengthen our mission to deliver accurate, reliable, and impactful diagnostic solutions for patients and providers.”

Advancing CNS Cancer Diagnostics

At CNSide Diagnostics, our mission is to transform cancer care by equipping clinicians with highly sensitive, CLIA-accredited cerebrospinal fluid (CSF) testing that supports:

• Early and accurate detection of tumor cells in the CNS
• Real-time monitoring of disease progression and treatment response
• Informed therapeutic decisions for improved patient outcomes

The addition of talented professionals like Tramel supports our commitment to innovation, laboratory excellence, and patient-centered diagnostics.

Learn More About Our Team and Mission

Meet the CNSide Team & Explore Our Mission: CNSide Mission & Values
About CNSide® Diagnostics: CNSide Official Website

#CNSide #Diagnostics #Biotech #Laboratory #LaboratoryTechnician #HealthcareInnovation #Oncology #CancerDiagnostics #PrecisionMedicine #LifeSciences #Biotechnology #Healthcare #NewHire